Composition and kit for diagnosing cancer and method for diagnosing cancer using same
OwnerDong Ha BHANGinventor
Life of this patent
Estimating the term…
Abstract
Provided are a composition and a kit for diagnosing bladder cancer, breast cancer, cervical cancer, colorectal cancer, gastric cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, and renal cancer, and a method for diagnosing cancer or a method for detecting a biomarker for diagnosing cancer, using the same. The present invention may be used as a composition or a kit for point-of-care testing-type diagnosis, and may diagnose bladder cancer, breast cancer, cervical cancer, colorectal cancer, gastric cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, and renal cancer with high accuracy, sensitivity, and specificity.
Claims19
-20. (canceled)
A composition for diagnosing gastric cancer, comprising:
- an agent for measuring the expression level of a gene or the expression level of a protein or a fragment thereof for a combination of anti-ECPKA antibody, anti-TK1 antibody, anti-granulin antibody, and anti-Her-2 antibody;
- and one or more biomarkers selected from the group consisting of anti-hP53 antibody, anti-c-myc antibody, AFP, and cTK1.
-55. (canceled)
-63. (canceled)
A kit for diagnosing gastric cancer, comprising:
- an agent for measuring the expression level of a gene or the expression level of a protein or a fragment thereof for a combination of anti-ECPKA antibody, anti-TK1 antibody, anti-granulin antibody, and anti-Her-2 antibody;
- and one or more biomarkers selected from the group consisting of anti-hP53 antibody, anti-c-myc antibody, AFP, and cTK1.
-74. (canceled)
A method for detecting a biomarker for diagnosing gastric cancer, comprising the steps of:
- measuring the expression level of a gene or the expression level of a protein or a fragment thereof for a combination of anti-ECPKA antibody, anti-TK1 antibody, anti-granulin antibody, and anti-Her-2 antibody;
- and one or more biomarkers selected from the group consisting of anti-hP53 antibody, anti-c-myc antibody, AFP, and cTK1 in a biological sample isolated from a subject suspected of having gastric cancer;
- and
- comparing the measured expression level with the expression level of a gene or the expression level of a protein or a fragment thereof in a normal control group.
-81. (canceled)
Dependencies are inferred from the claim text.